Pancreatic Cancer Research

ResearcherGuangdong General HospitalActive in the last 2 years

Baohua Hou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4239-1367; OpenAlex author ID A5034262385. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 9 papers · 2021: 6 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 32

  1. Multi-omics analysis identifies PUS7 as an immune modulator driving NETs-mediated macrophage polarization in pancreatic cancer. Co-author DOI 10.1002/ctm2.70581↗
  2. LINC00476 cooperates with ARIH2 and suppresses pancreatic cancer progression by inducing VIM ubiquitination. Last author DOI 10.1097/js9.0000000000003596↗
  3. Nuclear magnetic resonance-based metabolomics and risk of pancreatic cancer: a prospective analysis in the UK Biobank. Co-author DOI 10.1007/s00535-025-02237-9↗
  4. Associations between triglyceride-glucose related indices and the risk of incident pancreatic cancer: a large-scale prospective cohort study in the UK Biobank. Co-author DOI 10.1186/s12885-025-13718-8↗
  5. Integrated scRNA-seq and transcriptome analyses uncover the effects of UBE2H on the immune microenvironment regulation in pancreatic cancer. Last author DOI 10.1186/s12935-025-04059-4↗
  6. Prognostic significance of glucose-lipid metabolic index in pancreatic cancer patients with diabetes mellitus. Co-author DOI 10.1002/cam4.7108↗
  7. Identification and validation of stemness-based and ferroptosis-related molecular clusters in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2024.101877↗
  8. LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4. Co-author DOI 10.1186/s13062-024-00463-4↗
  9. A hierarchical prognostic model for Co-diabetes pancreatic adenocarcinoma. Last author DOI 10.1016/j.heliyon.2023.e21642↗
  10. Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of… Last author DOI 10.1016/j.heliyon.2022.e11321↗
  11. Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer. Last author DOI 10.1155/2022/4269733↗
  12. ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway. Last author DOI 10.1186/s13046-022-02310-8↗
  13. Prognostic values and immune suppression of the S100A family in pancreatic cancer. Last author DOI 10.1111/jcmm.16343↗
  14. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2021/6682697↗
  15. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. Last author DOI 10.1155/2021/9949272↗
  16. Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Last author DOI 10.1177/11795549211024149↗
  17. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. Last author DOI 10.7150/jca.57082↗
  18. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Last author PMID 34249426↗
  19. FAM83H overexpression predicts worse prognosis and correlates with less CD8+ T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer. Last author DOI 10.1007/s12094-020-02365-z↗
  20. GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer. Last author DOI 10.1042/bsr20202150↗
  21. Establishment of a 7-miRNA-Based Risk Score System for Predicting Prognosis of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001542↗
  22. Down-regulated lncRNA SBF2-AS1 in M2 macrophage-derived exosomes elevates miR-122-5p to restrict XIAP, thereby limiting pancreatic cancer development. Co-author DOI 10.1111/jcmm.15125↗
  23. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Last author DOI 10.1111/jcmm.15990↗
  24. A four prognosis-associated lncRNAs (PALnc) based risk score system reflects immune cell infiltration and predicts patient survival in pancreatic cancer. Last author DOI 10.1186/s12935-020-01588-y↗
  25. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1186/s13014-020-01511-9↗
  26. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. Last author DOI 10.18632/aging.202255↗
  27. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Last author DOI 10.21037/atm.2020.03.98↗
  28. Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis. Co-author DOI 10.2147/cmar.s196951↗
  29. Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.00773↗
  30. Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3806-x↗
  31. Association and Intragenic Single-Nucleotide Polymorphism Interactions of the XRCC1 Polymorphisms for Pancreatic Cancer Susceptibility. Co-author DOI 10.1097/mpa.0000000000000482↗
  32. [Expression of miR-216a in pancreatic cancer and its clinical significance]. Co-author PMID 23174591↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chuanzhao Zhang · 24 shared papers, 2018–2026 · strength 4.01
  2. Shanzhou Huang · 21 shared papers, 2020–2026 · strength 3.61
  3. Zuyi Ma · 17 shared papers, 2020–2025 · strength 2.50
  4. Hongkai Zhuang · 16 shared papers, 2020–2024 · strength 2.20
  5. Zixuan Zhou · 14 shared papers, 2020–2024 · strength 1.82
  6. Zhenchong Li · 12 shared papers, 2020–2026 · strength 1.77
  7. Shiye Ruan · 6 shared papers, 2019–2026 · strength 1.19
  8. Qi Zhou · 6 shared papers, 2021–2025 · strength 1.07
  9. Zelong Wu · 5 shared papers, 2023–2025 · strength 1.07
  10. Zhongyan Zhang · 3 shared papers, 2024–2025 · strength 0.67
  11. Yuanfeng Gong · 5 shared papers, 2020–2021 · strength 0.60
  12. Yiping Zou · 5 shared papers, 2020–2021 · strength 0.58
  13. Shujie Wang · 4 shared papers, 2021–2023 · strength 0.58
  14. Jike Fang · 2 shared papers, 2026 · strength 0.56
  15. Zhixiang Jian · 6 shared papers, 2012–2020 · strength 0.51
  16. Hailiang Wang · 2 shared papers, 2024 · strength 0.42
  17. Min Yu · 4 shared papers, 2018–2020 · strength 0.39
  18. Bowen Huang · 3 shared papers, 2021 · strength 0.34
  19. Haosheng Jin · 3 shared papers, 2019–2020 · strength 0.31
  20. Qian Yan · 1 shared paper, 2026 · strength 0.26
  21. Fuxin Huang · 1 shared paper, 2025 · strength 0.26
  22. Bo Chen · 2 shared papers, 2021 · strength 0.25
  23. Ning Shi · 2 shared papers, 2020 · strength 0.24
  24. Zi Yin · 2 shared papers, 2018–2020 · strength 0.20
  25. Yu Zhou · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.